Beth-Ann Coller Ph.D., Executive Director, Global Clinical Development at Merck & Co., Inc., Kenilworth, NJ, USA and former Senior Vice President for Research and Development at Hawaii Biotech, Inc., has more than 25 years of post-doctoral viral vaccine research and development experience. Dr. Coller received her Ph.D. in 1993 from the University of Nebraska Medical Center, where she studied the molecular virology of picornaviruses. She then joined Hawaii Biotech where her efforts focused on development of vaccines based on recombinant subunit approaches. In 1999, Dr. Coller joined GlaxoSmithKline Biologicals in Rixensart, Belgium where she was the project manager for the dengue vaccine project and led the Preclinical Virology Group which was responsible for preclinical development of all viral vaccine projects. In September 2004 Dr. Coller rejoined Hawaii Biotech and was ultimately responsible for all Research and Development activities. In August 2010, Dr. Coller joined Merck to support dengue vaccine development and since then has expanded her responsibilities. She is currently the Product Development Team Leader for the Ebola and Dengue vaccine programs at Merck.